Improved Vascular Engraftment and Graft Function After Inhibition of the Angiostatic Factor Thrombospondin-1 in Mouse Pancreatic Islets

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Published Version</td>
<td>doi://10.2337/db07-0724</td>
</tr>
<tr>
<td>Citable link</td>
<td><a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:8097016">http://nrs.harvard.edu/urn-3:HUL.InstRepos:8097016</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA">http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA</a></td>
</tr>
</tbody>
</table>
OBJECTIVE—Insufficient development of a new intra-islet capillary network after transplantation may be one contributing factor to the failure of islet grafts in clinical transplantation. The present study tested the hypothesis that the angiostatic factor thrombospondin-1 (TSP-1), which is normally present in islets, restricts intra-islet vascular expansion posttransplantation.

RESEARCH DESIGN AND METHODS—Pancreatic islets of TSP-1−/− deficient (TSP-1−/−) mice or wild-type islets transfected with siRNA for TSP-1 were transplanted beneath the renal capsule of syngeneic or immunocompromised recipient mice.

RESULTS—Both genetically TSP-1−/− islets and TSP-1 siRNA-transfected islet cells demonstrated an increased vascular density when compared with control islets 1 month after transplantation. This was also reflected in a markedly increased blood perfusion and oxygenation of the grafts. The functional importance of the improved vascular engraftment was analyzed by comparing glucose-stimulated insulin release from islet cells transfected with either TSP-1 siRNA or scramble siRNA before implantation. These experiments showed that the increased revascularization of grafts composed of TSP-1 siRNA-transfected islet cells correlated to increments in both their first and second phase of glucose-stimulated insulin secretion.

CONCLUSIONS—Our findings demonstrate that inhibition of TSP-1 in islets intended for transplantation may be a feasible strategy to improve islet graft revascularization and function. Diabetes 57:1870–1877, 2008

D espite improvements in immunosuppression protocols over the last years, pancreatic islets from at least two donor pancreata are still needed to reverse type 1 diabetes in clinical islet transplantation (1,2). This is far more than the alleged 10–20% of the total islet volume suggested to be enough to maintain normoglycemia in humans. Moreover, in contrast to the results for whole-organ transplantation, there seems to be a continuous decline in islet graft function, and very few patients remain insulin-independent at 5 years posttransplantation (2,3). Because the histocompatibility barrier, the underlying autoimmune disease, and the immunosuppressive agents used are the same for both transplantation procedures, it is likely that issues related to the adaptation of the implanted islets to their new microenvironment play a role for the differences in results.

Pancreatic islets become disconnected from their vascular supply during collagenase digestion before transplantation. Revascularization of transplanted islets has been shown to be concluded within 7–14 days (4). However, the resulting vascular density remains lower than in endogenous islets (5–7) and is associated with an impaired oxygenation (6,8) and endocrine function (7,9,10).

We have recently observed that freshly isolated rodent islets become better revascularized and function better than islets cultured for several days before transplantation (11), although the islet vascular system, also when using freshly isolated islets for transplantation, is far from fully restored. One possible explanation for the improved vascular engraftment in such islets is that not only host blood vessels but also remnants donor islet endothelial cells may participate in the formation of a new islet vascular network (12–14). However, despite the presence of several mitogens for endothelial cells within the islets, such as vascular endothelial growth factor (VEGF), fibroblast growth factor, and matrix metalloproteinases (15–17), intra-islet endothelial cells normally have a very low proliferation rate (18,19). This endothelial quiescence is presumably due to the fact that pro-angiogenic factors normally are counteracted by anti-angiogenic factors present in the islets (20), including the islet endothelial cells themselves (21,22). A possible key factor in this context is thrombospondin-1 (TSP-1), because it is not downregulated by hypoxia (20), which occurs posttransplantation. Moreover, animals deficient of this glycoprotein are characterized by hypervascular islets (23). The present study tested the hypothesis that use of genetically TSP-1−/− islets or transfection of islets in vitro with siRNA for TSP-1 would create a microenvironment permissive for blood vessel growth within islets and improve vascular engraftment and function after transplantation.

RESEARCH DESIGN AND METHODS

Pancreatic islets from wild-type (TSP-1+/−), heterozygous TSP-1+/−, and TSP-1−/− C57BL/6 mice of the F2-F3 generations were used for transplantation. The TSP-1−/− mice were generated by homologous recombination in 129Sv-derived ES cells implanted in C57BL/6 blastocysts (24). A breeding program of such mice was established at Uppsala University, and male mice 10–12 weeks of age were allocated to the studies. Age-matched wild-type male C57BL/6 mice were used as controls. Recipient C57BL/6 (nu/nu) mice weighing ~30 g were purchased from M&B Research and Breeding Center (Ry, Denmark). For experiments with siRNA, adult, inbred C57BL/6 mice (M&B) were used both as islet donors and recipients. All animals had free access to

From the 1Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden; the 2Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts; and the 3Department of Medical Sciences, Uppsala University, Uppsala, Sweden. Corresponding author: Per-Ola Carlsson, per-ola.carlsson@mcb.uu.se. Received 28 May 2007 and accepted 10 April 2008. Published ahead of print at http://diabetes.diabetesjournals.org on 16 April 2008. DOI: 10.2337/db07-0724. © 2008 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Capillary SYBR Green qPCR kit (Finnzymes).

/H9252 with a Lightcycler system (Roche-Diagnostic, Lewes, U.K.) using DyNA

Mold (Moloney murine leu-

kemia virus) II (Finzymes, Espoo, Finland). Amplification was obtained with a Lightcycler system (Roche-Diagnostic, Lewes, U.K.) using DyNaMold Capillary SYBR Green qPCR kit (Finzymes). β-Actin was used as house-

keeping gene. For primer sequences used, see Table 1.

<table>
<thead>
<tr>
<th>Gene/siRNA number</th>
<th>Primer/siRNA sequence (5’–3’).</th>
</tr>
</thead>
<tbody>
<tr>
<td>NM_007393</td>
<td>GACTCTGGCTTCTGACCC</td>
</tr>
<tr>
<td>NM_011580</td>
<td>GGAACGCCAAGACCAACTG</td>
</tr>
<tr>
<td>Scramble siRNA†</td>
<td>CAGUCGCUUUGGCAGCUAG</td>
</tr>
<tr>
<td>TSP-1 siRNA 1‡</td>
<td>GAUGACUACGCGUCGUUGUGU</td>
</tr>
<tr>
<td>TSP-1 siRNA 2‡</td>
<td>GCCUGAAGAAAGACGCUU</td>
</tr>
<tr>
<td>TSP-1 siRNA 3‡</td>
<td>CAAAGGCUCUGACGCCUU</td>
</tr>
<tr>
<td>TSP-1 siRNA 4‡</td>
<td>CAACUGGCAAACUGGUCCU</td>
</tr>
</tbody>
</table>

†Primers ordered from MWG Biotech (Ebersberg, Germany).
‡Scramble siRNA sequence ordered from Dharmacon Research (Chicago).

Evaluation of islet graft function. Grafs from some of the animals transplanted with scramble or TSP-1 siRNA-transfected wild-type islets
perfusion pressure of administered at a rate of 1 ml/min without recycling for 60 min with a Statistical analysis. The area under the curve (AUC) was then determined from these values. was calculated by multiplying the insulin concentration in the sample by samples were measured by ELISA (Mercodia). The rate of insulin secretion was concluded by a 15-min perfusion with medium containing 2.8 mmol/l glucose. A 1.0-ml sample was collected at 14, 15, 16, 17, 18, 19, 20, 22, 25, 30, 35, 40, 45, 50, 55, and 60 min. The insulin concentrations of the effluent medium contained either 2.8 or 16.7 mmol/l D-glucose. The medium was Krebs-Ringer bicarbonate buffer supplemented with 2.0% (wt/vol) each of BSA (fraction V; Miles Laboratories, Slough, U.K.) and dextran T70 (Pharmacia, Uppsala, Sweden). At different times during the perfusion, the medium was administered at a rate of 1 ml/min without recycling for 60 min with a perfusion pressure of ~40 mmHg. The perfusion experiments started with a 15-min period using medium containing 2.8 mmol/l glucose, which was followed by 30 min using 16.7 mmol/l glucose. A 1.0-ml sample was collected at 14, 15, 16, 17, 18, 19, 20, 22, 25, 30, 35, 40, 45, 50, 55, and 60 min. The insulin concentrations of the effluent samples were measured by ELISA (Mercodia). The rate of insulin secretion was calculated by multiplying the insulin concentration in the sample by the flow rate, giving values of insulin expressed as nanograms per minute. The area under the curve (AUC) was then determined from these values.

**Statistical analysis.** Values are expressed as the means ± SE. For comparisons of parametric data, Student’s paired or unpaired two-tailed t test was used. For all comparisons, P values <0.05 were considered statistically significant.

**RESULTS**

**Animal characteristics.** All recipient mice allocated to the study weighed ~30 g at transplantation and had increased 5–10% in body weight when investigated 1 month later. Both donors of islets, including the TSP-1+/− mice, and recipients were normoglycemic with nonfasting blood glucose concentrations of ~7 mmol/l. All animals allocated to blood flow and oxygen tension measurements had a mean arterial blood pressure of 90–100 mmHg. No animals had to be excluded based on the preset exclusion criteria for blood gases and hematocrit. However, two animals were excluded from studies of islet graft blood flow and oxygen tension because of hypotension (mean arterial blood pressure <75 mmHg) following perioperative bleeding.

**Expression of TSP-1 in different organs.** TSP-1 immunoreactivity was observed as a double band. When compared with spleen, pancreatic islets and kidneys contained low amounts of the protein TSP-1 (Fig. LA).

**Expression of TSP-1 mRNA and protein in islet cells after siRNA transfection.** Dispersed islet cells transfected with TSP-1 siRNA showed an ~40% reduction in...
TSP-1 mRNA expression compared with dispersed islet cells transfected with scramble siRNA when evaluated 24 h posttransfection (Fig. 1B). At the protein expression level, the effects of TSP-1 siRNA transfection caused a delayed effect, with a ~40% decrease first after 1 week (Fig. 1C and D).

**Effects of TSP-1 siRNA transfection on islet function.** There were no differences in insulin release at low glucose concentrations (50.2 ± 5.5 vs. 47.2 ± 6.7 ng⋅μg DNA⁻¹⋅h⁻¹), in insulin release at high glucose concentrations (203.0 ± 18.8 vs. 187.2 ± 19.3 ng⋅μg DNA⁻¹⋅h⁻¹), or in islet insulin content (8.2 ± 0.1 vs. 7.5 ± 0.3 ng/ng DNA) between islet cells transfected with scramble siRNA or TSP-1 siRNA 72 h before measurements.

**Blood flow.** One month posttransplantation, the blood perfusion of grafts composed of wild-type control islets or scramble siRNA-transfected islet cells were similar and 40–50% of that in the adjacent renal cortex (Fig. 2A and B, respectively). In comparison, grafts composed of islet tissue either genetically decreased or deficient in TSP-1 (Fig. 2A) or transfected with siRNA for TSP-1 (Fig. 2B) had a markedly higher blood perfusion when compared with their corresponding control.

**Oxygen tension.** The pO₂ levels in islet grafts composed of wild-type control islets (Fig. 3A) or in islet cells transfected with scramble siRNA before transplantation (Fig. 3B) were 7–8 mmHg 1 month posttransplantation. Improved oxygenization compared with this was observed in islet grafts composed of TSP-1⁺⁻ islets, TSP-1⁻⁻ islets, or islet cells transfected with TSP-1 siRNA before transplantation (Fig. 3A and B, respectively).

**Vascular density.** Both wild-type control islets (Fig. 4A and B) and scramble siRNA-transfected islet tissue (Fig. 4D and E) had a blood vessel density of ~7% 1 month posttransplantation. By contrast, both TSP-1⁻⁻ islets (Fig. 4A and C) and islet tissue transplanted with siRNA for TSP-1 (Fig. 4D and F) had an ~40% increase in vascular density. Islet grafts composed of TSP-1⁺⁻ islets had a vascular density in-between wild-type islet grafts and TSP-1⁻⁻ islet grafts (Fig. 4A). The increase in blood vessels numbers seemed to occur both in the center and

---

**FIG. 2. Blood flow in renal subcapsular islet grafts and adjacent renal cortex 1 month posttransplantation. A:** The islet grafts were composed of 250 wild-type (■), TSP-1⁻⁻ (■), or TSP-1⁻⁻ (□) islets. *P ≤ 0.003 when compared with wild-type islets. #P = 0.04 when compared with TSP-1⁺⁻. **B:** The islet grafts were composed of 250 scramble (■) or TSP-1 siRNA-transfected (□) islets. *P = 0.04 when compared with scramble siRNA transfected islets. Blood flow values are expressed as TPU. Values are means ± SE for six experiments in each group.

**FIG. 3. Oxygen tension in renal subcapsular islet grafts and adjacent renal cortex 1 month posttransplantation. A:** The islet grafts were composed of 250 wild-type (■), TSP-1⁻⁻ (■), or TSP-1⁻⁻ (□) islets. **B:** The islet grafts were composed of 250 scramble (■) or TSP-1 siRNA-transfected (□) islets. Values are means ± SE for six experiments in each group. *P ≤ 0.001 when compared with control islets (■) in both A and B. #P = 0.003 when TSP⁻⁻ was compared with TSP⁺⁻.
FIG. 4. Vascular density in renal subcapsular islet grafts 1 month posttransplantation. A: Percentage of islet area constituted by blood vessels in islet grafts composed of wild-type (■), TSP-1−/− (□), or TSP-1+/− (□) islets. *P = 0.046 when compared with wild-type islets. B and C: Micrographs of islet grafts composed of wild-type (B) or TSP-1−/− (C) islets stained with the endothelial marker BS-1 (red). D: Percentage of islet area constituted by blood vessels in islet grafts composed of scramble (■) or TSP-1 siRNA-transfected (□) islets. *P = 0.016 when compared with scramble siRNA-transfected islets. E and F: Micrographs of islet grafts composed of scramble (E) or TSP-1 (F) siRNA-transfected islets. Values in A and D are means ± SE for five to eight (A) and four experiments in each group, respectively. Scale bars in micrographs are 50 μm.

Peripheral regions of the TSP-1−/− islets and TSP-1 siRNA-transfected islet tissue.

Islet transplant cell composition. There were similar percentages of β-cells in grafts composed of wild-type islets or TSP-1−/− islets (84.7 ± 1.3% [n = 4] vs. 86.2 ± 0.9% [n = 5], respectively). Likewise, there was no difference in β-cell percentage in the islet tissue composed of scramble siRNA-transfected and TSP-1 siRNA-transfected islet cells at 1 month follow-up (85.1 ± 0.5 vs. 86.9 ± 1.3%, respectively).

Islet graft function. Perfusion of islet graft–bearing kidneys 1 month posttransplantation showed that islet tissue transfected with siRNA for TSP-1 had an improved first and second peak of insulin release when compared with scramble siRNA-transfected islet cells (Fig. 5A–C). Total AUC for glucose-stimulated insulin release in the TSP-1 siRNA-transfected islet tissue was thus increased by ~40% (Fig. 5D).

Discussion

Adult pancreatic islets have a dense glomerular-like angiarchitecture that requires VEGF-signaling from the β-cells for its formation and maintenance (31–34). However, despite chronic exposure to VEGF, vascular expansion does not normally occur in islets after the 1st postnatal week (35). Likewise, although increased amounts of not only VEGF but also other pro-angiogenic factors such as hepatocyte growth factor are secreted from newly transplanted islets (16,36), new blood vessel formation within the islets also during these conditions is sparse (5–7). Instead, a rich vascular network is formed in the stroma around each single transplanted islet (5). This suggests the presence of matrix- or tissue-bound angiostatic factors within the implanted islets that prevent intra-islet vascular formation. Marked overexpression of VEGF in the donor tissue has previously been shown in experimental studies to overcome this and to improve islet graft revascularization and function (9,10). However, silencing some of the angiostatic factors may be an even simpler strategy.

In this study, we tested the hypothesis that unopposing the action of already-present pro-angiogenic factors through silencing TSP-1 in islets would improve islet graft revascularization and function. The glycoprotein TSP-1 binds to the extracellular matrix (37,38) and exerts its main effects through blocking the activation of endothelial cells, i.e., those that are forming new blood vessels, but not quiescent endothelium (39). It also inhibits angiogenesis by blocking the mobilization of pro-angiogenic factors, such as matrix metalloproteinase-9 and VEGF, and by inhibiting their access to co-receptors on the endothelial cell surface (40).

We investigated the influence of TSP-1 on islet graft revascularization using two different models: by transplanting genetically TSP-1 deficient islets and by transplanting islet cells transfected with siRNA for TSP-1 in vitro before transplantation. The first model thereby provides a persistent partial (TSP-1+/-) or complete loss (TSP-1−/−) of TSP-1 expression in the islets, whereas the latter causes only a transient decrease in TSP-1 levels. Using both approaches, we observed a markedly improved vascular engraftment of the transplanted islets with improved intra-islet vascular density at 1 month follow-up. In both models, the newly formed blood vessels also seemed to be functional, because the improved vascular density was reflected in an increased blood perfusion and pO2 in the islet grafts. Notably, the pO2 increase was especially prominent in the TSP-1−/− mice, where TSP-1 expression is chronically deficient and of a greater magnitude than the
increase in blood vessel numbers. It is possible that this reflects higher blood perfusion in individual blood vessels and thereby better oxygen transport capacities of islet blood vessels in the absence of TSP-1, e.g., due to loss of the previously described counteracting effect of TSP-1 on nitric oxide–mediated vasodilation (41). Nitric oxide is the main mediator of high blood perfusion in endogenous and transplanted islets (42,43). It should be noted that an intra-islet vasodilation is not necessarily reflected in increased total graft blood flow, which is measured by laser-Doppler flowmetry, because total graft blood flow represents not only the nutritive blood flow to the endocrine cells but also blood flow in the vast number of stroma capillaries. In contrast, it could be expected that the blood flow in capillaries in the endocrine parts mainly contributes to the delivery of oxygen to the endocrine cells due to limitations of oxygen diffusion (44).

In our characterization of TSP-1−/− mice, we observed that these mice had fasting and nonfasting blood glucose levels that were normal and did not differ from those of wild-type animals. However, despite that TSP-1−/− mice have been described to have an increased islet mass (23), closer investigations revealed that these animals were slightly glucose intolerant and had a decreased islet function (45), which probably reflects the role of TSP-1 in transforming growth factor-β1 activation (23). Nevertheless, we hypothesized that a transient decrease in islet TSP-1 levels during the acute revascularization phase of transplanted islets may still be beneficial for long-term islet function, considering that such a decrease also can be seen physiologically during the islet vascular expansion of pregnant rats. In our protocol for TSP-1 siRNA transfection of islet cells using Lipofectamine as vector, there was a transient decrease in islet TSP-1 levels at the mRNA and protein levels of a similar magnitude as seen in islets during pregnancy, i.e., 40%. In rapidly dividing cells, the silencing effect of siRNA usually lasts for 1 week, but it lasts for up to 3–4 weeks in nondividing cells both in vitro and in vivo (46). Probably because of the low proliferation rate of adult endocrine cells, including β-cells, and turnover rate of the extracellular matrix binding of the TSP-1 protein, silencing of TSP-1 in these cells was not manifested until after 1 week at the protein level. A partial effect of TSP-1 siRNA may also be on the remnant donor islet endothelial cells, because these cells also contain TSP-1 (22). However, in this

![Graph A](https://via.placeholder.com/150)

**FIG. 5.** Functional studies with perfusions of renal subcapsular islet grafts 1 month posttransplantation. **A:** Insulin release in response to 16.7 mmol/l glucose (bar) from grafts composed of 250 scramble (●) or TSP-1 siRNA-transfected islets (○). **B–D:** AUC for the first phase (B) of glucose-stimulated insulin release (min 14–18; *P = 0.006 when compared with control), the second phase (C) of glucose-stimulated insulin release (min 19–50; *P = 0.041 when compared with control), and both the first and second phase (D) of insulin release (min 14–50; *P = 0.025 when compared with control). Values are means ± SE for six experiments with all groups.
case, the effect is probably much shorter because of cell division as part of angiogenesis.

When graft function was evaluated by perfusion of graft-bearing kidneys 1 month posttransplantation, islet cells exposed to siRNA for TSP-1 before transplantation performed better than control islet cells exposed to scramble siRNA. The chosen model to evaluate graft function also enabled us to separately evaluate the effects of improved vascular engraftment on the insulin release kinetics from transplanted islets. It is noteworthy that the peak of the first phase of glucose-stimulated insulin secretion was substantially higher in the better revascularized islet grafts, which is similar to what we have previously observed when improving blood perfusion, but not revascularization, by angiotensin II receptor inhibition (47). However, in contrast to when only the blood perfusion was improved, we observed in the present study also an augmented second phase of glucose-stimulated insulin secretion. This suggests that the present findings do not merely reflect a “wash-out” effect of insulin retained in the islet grafts due to low blood perfusion. The general improvement of glucose-stimulated insulin release may in fact reflect an improved survival, a better oxygenation, and/or a better endothelial paracrine support of the islet β-cells. The normally low oxygenation of transplanted islets may affect islet survival and function, because it means that their metabolism tends to be much more anaerobic than that of endogenous islets and results in lactate formation and tissue acidosis (48). Several recent reports also indicate that endothelial cell signaling may be important for β-cell function and growth (19,49,50).

We conclude that transient inhibition of TSP-1 early posttransplantation may be used to improve islet graft revascularization and function. Such a strategy, e.g., by development of pharmacological inhibitors, may be more feasible in the clinical setting than trying to increase the expression of pro-angiogenic factors in the transplanted tissue even further.

ACKNOWLEDGMENTS
This work was supported by grants from The Swedish Research Council (55X-15043), The Juvenile Diabetes Research Foundation, the European Foundation for the Study of Diabetes/Juvenile Diabetes Research Foundation/Novo Nordisk Research Programme 2006, The Swedish Diabetes Association, The Swedish Juvenile Diabetes Fund, The Åner Foundation, and The Family Ernfrs Fund.

The skilled technical assistance of Astrid Nordin, Birgitte Bodin, and Eva Tornelius is gratefully acknowledged.

REFERENCES
20. Tillmar L, Welsh N: In vitro cultured rat islets express genes that both prevent and promote angiogenesis. JOP 5:81–91, 2004